[{"orgOrder":0,"company":"Yao Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"YP05002","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Yao Pharma","amount2":2.0899999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.0899999999999999,"dosageForm":"Tablet","sponsorNew":"Yao Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Yao Pharma \/ Pfizer Inc"}]

Find Clinical Drug Pipeline Developments & Deals by Yao Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO Partnering at JPM
                          Not Confirmed
                          BIO Partnering at JPM
                          Not Confirmed

                          Details : The collaboration aims to advance YP05002, a small molecule product, targeting GLP-1R.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : $150.0 million

                          December 09, 2025

                          Lead Product(s) : YP05002

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Pfizer Inc

                          Deal Size : $2085.0 million

                          Deal Type : Collaboration

                          blank